Β-Thromboglobulin AND HEPARIN-NEUTRALISING ACTIVITY TEST IN CLINICAL CONDITIONS

O’Brien, J.R.; Etherington, M. D.; Shuttleworth, R.; Denham, M. J.; Fisher, M.; James, Gloria; Hassan, M.

doi:10.1016/s0140-6736(77)92412-6

Cited by 29 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the studies reported by Handin et al 112 and Neri Serneri et al 215 nearly all patients with myocardial infarction or angina had elevated levels of BTG or PF4, but in most of the other studies reported, wide overlaps with controls were found. A recent study found that 61% of patients with coronary artery disease admitted to a coronary care unit with symptoms of ischemic heart disease had normal BTG 112 Levine et al 169 Hughes et al 138 Nichols et al 216 Smitherman et al 288 Doyle et al 75 Sobel et al 290 Neri Serneri et al 215 de Boer et al 24 White and Marouf 335 Myocardial Infarction O'Brien et al 225 Denham et al 72 Handin etal. 112 Ludlamet al 179 Hughes et al 138 O'Brien et al 226 Cortellaro et al 58 Rasi et al 240 Nichols et al 216 Smitherman et al 288 Neri Serneri et al 215 de Boer et al 24 White and Marouf 335 Simmonds et al 281 No 269 Green etal.…”

Section: Referencementioning

confidence: 99%

“…The heparin thrombin clotting time has been shown to correlate with both platelet survival time and PF4 radioimmunoassay and has been reported to be abnormal in a number of thromboembolic disorders. 225,226,300 Finally, measurement of radioactive serotonin released from platelets in vitro in response to ADP or collagen may be used to study platelet release reaction in vivo. 126,162 Serotonin release has been reported to be reduced in the acute phase of myocardial infarction but increased in the recovery phase.…”

Section: Tests Of In Vivo Platelet Releasementioning

confidence: 99%

See 1 more Smart Citation

Platelet Consumption in Cardiovascular Disease

Ag¹,

Ac²,

Genton³

1982

Semin Thromb Hemost

View full text Add to dashboard Cite

Many tests have been devised to investigate the role of platelets in arterial or venous thromboembolism. The mechanisms of platelet reactivity that the tests have measured have been variable and the early studies have been of little value in determining the contribution of platelet consumption in thromboembolic diseases. More recently, tests of in vivo platelet release and of platelet survival and turnover have been introduced and thought to be of great potential in the investigation of thromboembolic disorders. However, the data published thus far using more tests are far from conclusive that platelet activation and consumption occurs in thromboembolic disorders associated with arteriosclerosis. It may be that they are neither sensitive nor specific enough to detect minor changes in platelet activation. There is, however, some consistency that in conditions involving the larger vessels, prosthetic surfaces, or in association with active and recurrent venous thromboembolism, platelet release and platelet consumption measured by platelet survival time may occur. In particular, the abnormal results are consistently found in acute and recurrent venous thromboembolism, cardiac valve replacement with the older prosthetic devices, and arteriosclerosis of the larger arteries with clinical episodes of thromboembolism. However, in coronary artery disease, cerebrovascular disease, and peripheral vascular disease, the data are inconclusive, probably because the tests lack sensitivity. In addition, the value of the tests in the management of patients with thromboembolic disorders appears to be limited.

show abstract

Section: Referencementioning

confidence: 99%

Section: Tests Of In Vivo Platelet Releasementioning

confidence: 99%

Platelet Consumption in Cardiovascular Disease

Ag¹,

Ac²,

Genton³

1982

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Therefore, plasma level of these proteins may reflect in vivo platelet function and a means of predicting and diagnosing thromboembolic disease (9). Raised plasma levels of these proteins have already been reported in several disease states (4,5,8,10,(14)(15)(16). Another substance which is released during platelet aggregation is the labile thromboxane A2 (7).…”

Section: Introductionmentioning

confidence: 99%

<i>In vivo </i>Platelet Release Reaction in Patients with Heart Valve Prosthesis

Cella¹,

Schivazappa²,

Casonato³

et al. 1980

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Platelets play an important role in the genesis of thromboembolic episodes frequently observed in patients following cardiac valve replacement. No simple and reliable method as yet exists for quantitating platelet function in vivo. Platelet-specific proteins, serum β -thromboglobulin related antigen and platelet factor 4 as well as thromboxane B₂ were measured in 50 healthy subjects and in 100 patients who had cardiac valve replacement at least 6 months previously; these were related to the type, site and number of valves replaced. Highly significant differences were observed in the mean plasma β-thromboglobulin related antigen, platelet factor 4 and thromboxane B₂ levels in patients compared with healthy controls. The elevated levels of platelet release products observed 6 months after cardiac valve replacement suggest a continuous activation by the prosthesis. No significant differences were observed in patients with different types and site of valve prosthesis.

show abstract

“…O’Brien et al 22) have recently reported that patients with acute myocardial infarction have increased β -TG levels and decreased heparin-neutralizing activity. Also Denham et al 23) reported that β-TG levels were elevated in the patients with acute myocardial infarction and the levels were higher in the patients accompanied by mural thrombi.…”

Section: Discussionmentioning

confidence: 99%

Study on the Platelet Factor and β-Thromboglobulin in the Patients with Ischemic Heart Disease

Kim

Huo

Kim

et al. 1986

Korean J Intern Med

View full text Add to dashboard Cite

The platelet factor 4 (PF4) and β-thromboglobulin (β-TG) were measured to evaluate the platelet activation in vivo in patients with ischemic heart disease. The results are summarized as follows: In patients with acute myocardial infarction, the PF4 and the β-TG levels were significantly higher compared to those of normal controls (P<0.005).In patients with angina pectoris, the PF4 and the β-TG levels were not signivicantly different from those of normal controls.A pattern of decline in the PF4 and the β-TG level was shown in patients with acute myocardial infarction by day 10. In conclusion, the measurement of PF4 and β-TG is a useful method to detect the platect activation in vivo in the patients with ischemic heart disease.

show abstract

Β-Thromboglobulin AND HEPARIN-NEUTRALISING ACTIVITY TEST IN CLINICAL CONDITIONS

Cited by 29 publications

References 10 publications

Platelet Consumption in Cardiovascular Disease

Platelet Consumption in Cardiovascular Disease

<i>In vivo </i>Platelet Release Reaction in Patients with Heart Valve Prosthesis

Study on the Platelet Factor and β-Thromboglobulin in the Patients with Ischemic Heart Disease

Contact Info

Product

Resources

About